# Candel Therapeutics, Inc. (CADL) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Candel Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/CADL/mda/fy2025/): filed 2026-03-12; accession 0001193125-26-103134 (https://www.sec.gov/Archives/edgar/data/1841387/000119312526103134/cadl-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/CADL/mda/fy2024/): filed 2025-03-13; accession 0000950170-25-038803 (https://www.sec.gov/Archives/edgar/data/1841387/000095017025038803/cadl-20241231.htm)
- [FY 2023 MD&A](/company/CADL/mda/fy2023/): filed 2024-03-28; accession 0000950170-24-037637 (https://www.sec.gov/Archives/edgar/data/1841387/000095017024037637/cadl-20231231.htm)
- [FY 2022 MD&A](/company/CADL/mda/fy2022/): filed 2023-03-30; accession 0000950170-23-010760 (https://www.sec.gov/Archives/edgar/data/1841387/000095017023010760/cadl-20221231.htm)
- [FY 2021 MD&A](/company/CADL/mda/fy2021/): filed 2022-03-29; accession 0000950170-22-004857 (https://www.sec.gov/Archives/edgar/data/1841387/000095017022004857/cadl-20211231.htm)

Back to /company/CADL/